$LXEO

Stifel reiterated its Buy rating on Lexeo Therapeutics (LXEO) with a $17 price target, citing management's confidence in achieving a 15% effect size in a pivotal study. The stock trades at $3.53, below the analyst consensus range of $9 to $30. Lexeo completed the acquisition of Mantle Therapeutics for $8.3 million, adding new programs to its Friedreich’s ataxia portfolio. Baird and Raymond James also reiterated positive ratings with higher price targets.

Lexeo Therapeutics (LXEO) will present data on LX2006, its gene therapy for Friedreich ataxia, at the International Congress of Parkinson’s Disease and Movement Disorders 2026. The presentation will highlight early stabilization or improvement in mFARS scores and new subscore analyses, reinforcing LX2006's potential to address the disease's multisystem burden. LX2006 is in Phase 2 trials and has received multiple FDA designations.

Lexeo Therapeutics, Inc. (LXEO) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposal of Assets. At the effective time of the Merger (the “ Effective Time ”), each outstanding share of Mantle capital stock (other than shares held by Mantle as treasury shares, shares held by Lexeo or Merger Sub, and Dissenting Shares)

Lexeo Therapeutics CFO Louis Edward Tamayo received 54,750 stock options, exercisable at $3.39 per share. 25% vest on September 24, 2027, with monthly vesting thereafter, expiring September 23, 2036, subject to continuous service.

Leerink Partners kept an Outperform rating and $15 price target on Lexeo Therapeutics, implying 268.6% upside from its Sep 22 close. The firm cited strong clinical data for LX2006, targeting Friedreich ataxia cardiomyopathy, and strategic collaborations to address gene therapy challenges.

Apertura Gene Therapy will provide Lexeo Therapeutics (LXEO) with access to TfR1 CapX™ for a Friedreich ataxia treatment program. TfR1 CapX is an intravenously delivered AAV capsid designed to cross the blood-brain barrier. Lexeo's CFO expressed excitement about the partnership and its potential to address unmet needs in FA patients.

Lexeo Therapeutics (NASDAQ:LXEO) shares rose 5.4% premarket after announcing a deal to acquire Mantle Therapeutics for up to $21.3M, expanding its Friedreich ataxia treatment platform. The acquisition includes four therapeutic programs, with $8.3M upfront payment and $13M in potential milestones. Lexeo also launched three research collaborations and expects to submit an IND in 2027. Raymond James reiterated a Strong Buy rating and $24.00 price target.

U.S. stock futures were mixed on Tuesday. Ericsson (NASDAQ:ERIC) fell 4.3% to $9.81 after a Morgan Stanley analyst downgraded it and cut the price target. Other stocks moving lower include Quest Diagnostics (NYSE:DGX), Rambus (NASDAQ:RMBS), and Lexeo Therapeutics (NASDAQ:LXEO).

Lexeo Therapeutics, Inc. (LXEO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace f

Lexeo Therapeutics, Inc. (LXEO) reported beneficial ownership disclosures by OrbiMed entities. OrbiMed Advisors LLC holds 3,203,050 shares, about 4.1% of the class, and OrbiMed Capital LLC holds 744,800 shares, about 1.0%. Combined, they report 5.0% ownership with shared voting and dispositive control via a management committee.